# Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma

> **NCT07416890** · PHASE2 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 24 (estimated)

## Conditions studied

- Pirtobrutinib
- Sintilimab
- Central Nervous System Lymphoma

## Interventions

- **DRUG:** Thiotepa, Pirtobrutinib , Sintilimab(TPS)

## Key facts

- **NCT ID:** NCT07416890
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-10
- **Primary completion:** 2028-08-05
- **Final completion:** 2030-08-05
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07416890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07416890, "Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07416890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*